Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy | Zendy

Augusto Nogueira | Zendy; Raquel Catarino | Zendy; Ana Coelho | Zendy; António Araújo | Zendy; Mónica Gomes | Zendy; Rui Medeiros | Zendy

Open Access

Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy

Author(s) -

Augusto Nogueira,

Raquel Catarino,

Ana Coelho,

António Araújo,

Mónica Gomes,

Rui Medeiros

Publication year - 2009

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-009-1187-2

Subject(s) - lung cancer , genotype , rad51 , oncology , medicine , gemcitabine , chemotherapy , biology , survival rate , allele , cancer , dna repair , gene , genetics

Lung cancer continues to be the most frequent cancer with approximately one million people worldwide dying of this disease each year. Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. The RAD51 protein is the key protein for homologous recombination, an evolutionarily conserved mechanism for DNA damage repair and the generation of genetic diversity. We conducted this study in order to investigate the effect of the RAD51 G135C polymorphism in treatment response to combined platinum taxanes/gemcitabine first line chemotherapy in NSCLC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research